ES2574988T3 - Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa - Google Patents

Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa Download PDF

Info

Publication number
ES2574988T3
ES2574988T3 ES09749196.3T ES09749196T ES2574988T3 ES 2574988 T3 ES2574988 T3 ES 2574988T3 ES 09749196 T ES09749196 T ES 09749196T ES 2574988 T3 ES2574988 T3 ES 2574988T3
Authority
ES
Spain
Prior art keywords
integrase
hiv
stimulants
rev
interfere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09749196.3T
Other languages
English (en)
Inventor
Aviad Levin
Zvi Hayouka
Assaf Friedler
Abraham Loyter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of ES2574988T3 publication Critical patent/ES2574988T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un péptido constituido por la secuencia WGSNFTSTTVKA (SEQ ID NO: 5), WTAVQMAVFIHNFKRK (SEQ ID NO: 6), o WTHLEGKIILVAVHVA (SEQ ID NO: 7).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
5 10 15 20 25
las células infectadas por el virus por lo tanto puede servir como un péptido líder para obtener moléculas pequeñas que eliminarán selectivamente las células infectadas por virus y por lo tanto funcionan como medicamento contra el VIH. [0106] Figura 7 Porcentaje de células HeLa infectadas y no infectadas viables normalizadas cada dos días al número de células en la muestra de células no tratadas no infectadas. Las células fueron infectadas con WT VIH-1 a una MOI de 0,01 y se añadieron las células tratadas 12,5 µM de INS. [0107] Figura 8 Células fueron tratadas con péptidos INS o INrs o una mezcla de los tres péptidos en la concentración designada a continuación, las células se infectaron con MOI 10 de ∆ENV/VSV-G de VIH-1 que promueve un solo ciclo de infección. La prueba MTT se llevó a cabo después de la infección 48 h, y los valores se normalizaron a células no tratadas no infectadas. Ejemplo 5: Una combinación de péptidos INrs +INS y el inhibidor de proteasa de VIH-1 específica Ro 31-8959 erradica el VIH -1 [0108] Los resultados en la Fig 9 muestran que cuando los linfocitos H9 fueron tratados con una combinación de INr1, INr-2 y el INS y el inhibidor de proteasa de VIH-1 Ro 31 a 8.959, no se detectó ningún rastro de integración de virus o producción de virus después de 12 días. Parece que esta combinación da lugar a una completa erradicación del virus. [0109] Figura 9 células H9 fueron tratadas por el compuesto indicado (péptidos a 100 µM cada uno, el AZT a 2 µM o Ro31-8959 a 1 µM. Cóctel representa una mezcla o INS, INrs y Ro31-8959) e infectada con MOI de 0,1 en peso de VIH-1. Se estimaron cada 2 días la cantidad de partículas de virus infecciosas (A) y la cantidad de eventos de integración por célula (B) como se describe anteriormente.
30
35
40
45
50
55
15

Claims (1)

  1. imagen1
ES09749196.3T 2008-10-06 2009-10-01 Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa Active ES2574988T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10303608P 2008-10-06 2008-10-06
US103036P 2008-10-06
US22502809P 2009-07-13 2009-07-13
US225028P 2009-07-13
PCT/IL2009/000947 WO2010041241A2 (en) 2008-10-06 2009-10-01 Hiv-1 integrase derived peptides and compositions

Publications (1)

Publication Number Publication Date
ES2574988T3 true ES2574988T3 (es) 2016-06-23

Family

ID=42027886

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09749196.3T Active ES2574988T3 (es) 2008-10-06 2009-10-01 Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa

Country Status (5)

Country Link
US (2) US9163067B2 (es)
EP (1) EP2334318B1 (es)
ES (1) ES2574988T3 (es)
IL (1) IL212152B (es)
WO (1) WO2010041241A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334318B1 (en) * 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
US20140095361A1 (en) * 2012-09-28 2014-04-03 Oracle International Corporation Supply chain financial orchestration system with trade accounting
US10679166B2 (en) 2012-09-28 2020-06-09 Oracle International Corporation Supply chain financial orchestration system
US9767499B2 (en) 2012-09-28 2017-09-19 Oracle International Corporation Supply chain orchestration system with configure-to-order item matching
CN105209480B (zh) 2013-05-02 2019-08-16 法瑞斯生物技术有限公司 促转导素B(Protransduzin B)－基因转移的增强剂
US20200171159A1 (en) * 2017-05-21 2020-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective destruction of cells
EP3841108A4 (en) * 2018-08-23 2022-04-27 Zion Medical B.V. PHARMACEUTICAL COMPOSITIONS COMPRISING INTEGRATION-PROMOTING PEPTIDES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US20050271676A1 (en) 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
EP1078092B1 (en) 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
AU1075001A (en) 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
CA2447616A1 (en) 2001-05-18 2002-11-28 Deborah Fuller Vaccine composition
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
WO2004031210A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
BRPI0411127A (pt) 2003-06-10 2006-05-23 Univ Melbourne composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse
WO2005038028A1 (en) * 2003-10-15 2005-04-28 Virax Development Pty Ltd Poxvirus vector encoding retrovirus (eg hiv) and cytokine
US20080131451A1 (en) 2004-03-05 2008-06-05 Giancarlo Tanzi Epitope escape mutations
CA2568981A1 (en) 2006-02-24 2007-08-24 University Of Manitoba Integrase-derived hiv-inhibiting agents
WO2008053478A2 (en) 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2008068765A2 (en) 2006-12-07 2008-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
US20090092628A1 (en) * 2007-03-02 2009-04-09 James Mullins Conserved-element vaccines and methods for designing conserved-element vaccines
PL2003120T3 (pl) * 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
EP2334318B1 (en) * 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding

Also Published As

Publication number Publication date
EP2334318B1 (en) 2016-02-10
IL212152B (en) 2018-03-29
WO2010041241A3 (en) 2010-12-16
US20160032263A1 (en) 2016-02-04
US9738878B2 (en) 2017-08-22
US20110257082A1 (en) 2011-10-20
IL212152A0 (en) 2011-06-30
EP2334318A2 (en) 2011-06-22
WO2010041241A2 (en) 2010-04-15
US9163067B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
ES2574988T3 (es) Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa
Huang et al. The depolymerized fucosylated chondroitin sulfate from sea cucumber potently inhibits HIV replication via interfering with virus entry
Monette et al. Pan-retroviral nucleocapsid-mediated phase separation regulates genomic RNA positioning and trafficking
Rezelj et al. The defective component of viral populations
Diehl et al. Ebola virus glycoprotein with increased infectivity dominated the 2013–2016 epidemic
Oberste et al. Conservation of amino-acid sequence motifs in lentivirus Vif proteins
Urushisaki et al. Caffeoylquinic acids are major constituents with potent anti-influenza effects in brazilian green propolis water extract
CL2008003020A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado, que comprende generar celulas que expresan la proteina g de la vsv a partir de un gen vsv optimizado, infectar dichas celulas con el vsv atenuado, y recuperar los virus dle cultivo; composicion que comprende al virus atenuado y kit para producir el virus.
DE60327190D1 (de) Zellen zum nachweis von influenza- und parainfluenzaviren
Rumschlag-Booms et al. Development of an antiviral screening protocol: One-Stone-Two-Birds
Dilcher et al. Genetic characterization of Bhanja virus and Palma virus, two tick-borne phleboviruses
Contreras-Gutiérrez et al. Sinu virus, a novel and divergent orthomyxovirus related to members of the genus Thogotovirus isolated from mosquitoes in Colombia
Ballinger et al. Selectively maintained paleoviruses in Holarctic water fleas reveal an ancient origin for phleboviruses
Kading et al. Isolation and molecular characterization of Fikirini rhabdovirus, a novel virus from a Kenyan bat
Lei et al. Characterization of H5N1 influenza viruses isolated from migratory birds in Qinghai province of China in 2006
Wu et al. Super short membrane-active lipopeptides inhibiting the entry of influenza A virus
Matusevich et al. Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments
Paskaleva et al. Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme
MaE Potential Effect of Pomegranate Peels Extract (Punica Granatum.) against Covid-19 Virus.
Stoner et al. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir
Ndembi et al. HIV type 1 infection in Pygmy hunter gatherers is from contact with Bantu rather than from nonhuman primates
Siniavin et al. Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor
Bennett Bats and human emerging diseases
Orozco-García et al. Cell Biology of Virus Infection. The Role of Cytoskeletal Dynamics Integrity in the Effectiveness of Dengue Virus Infection
Shi et al. Study on the antiviral activities and hemagglutinin-based molecular mechanism of novel chlorogenin 3-O-β-chacotrioside derivatives against H5N1 subtype viruses